Fig. 4: LDC7559 inhibits G-MDSC and M-MDSC expansion and hematopoiesis in bone marrow of breast cancer model.

a FACS (Fluorescence-activated cell sorting) analysis of G-MDSC and M-MDSC in spleens of WT mice, 4T1-bearing mice or LDC7559 treated 4T1-bearing mice. b Quantification of the percentages of G-MDSC, M-MDSC, CD4⁺ T cells and CD8⁺ T cells in the spleen of indicated groups in (a). c Quantification of absolute cell number of G-MDSC, M-MDSC, CD4⁺ T cells and CD8⁺ T cells of whole spleen in WT, 4T1-bearing and LDC7559 treated 4T1-bearing mice. d FACS analysis of bone marrow G-MDSC and M-MDSC in wild type mice, 4T1 tumor bearing mice, or LDC7559 treated 4T1 tumor bearing mice. e Quantification of the frequency of G-MDSC and M-MDSC subsets in the bone marrow of indicated groups in (d). f Quantification of absolute cell number of G-MDSC and M-MDSC per tibia in WT, 4T1-bearing and LDC7559 treated 4T1-bearing mice. g FACS analysis of bone marrow lineage^-c-Kit⁺Sca-1⁺ (LK), lineage^-c-Kit⁺Sca-1^- cells (LSK), granulocyte-macrophage progenitors (GMP, lineage^-c-Kit⁺Sca-1⁺CD34⁺CD16/32⁺), common myeloid progenitors (CMP, lineage^-c-Kit⁺Sca-1⁺CD34⁺CD16/32^-) and megakaryocyte-erythroid progenitors (MEP, lineage^-c-Kit⁺Sca-1^-CD34^-CD16/32^-) in WT, 4T1-bearing and LDC7559 treated 4T1-bearing mice. h Quantification of the percentages of LK, LSK, GMP CMP and MEP in (g). i Quantification of absolute cell number of LK, LSK, GMP CMP and MEP in (g). n = 5 mice (b, c, e, f). n = 3 mice (h and i). Data are presented as means ± SEM. Significance was examined with two-tailed unpaired Student’s t test (b, c, e, f, h, i). ns not significant, ^*P < 0.05, ^**P < 0.01, ^***P < 0.001.